Sinopex, 'Lab On a Chip' Blood Cell Analysis Cartridge Patent Application

[Financial News] Sinopex announced on the 22nd that it has applied for a patent for a blood cell analysis cartridge applied to the blood cell analyzer 'Lumiio' with artificial intelligence (AI) technology.
The blood cell analysis cartridge is a core product that processes blood so that Lumiio's AI can perform image analysis on the blood to be tested.
This patent application technology is a 'Lab On a Chip' type blood cell analysis cartridge that enables blood analysis with just one drop of blood, a groundbreaking technology. In particular, it allows for blood cell analysis by automatically processing steps such as blood staining, mixing, smearing, and drying, which were previously done manually, within the cartridge.
Sinopex's blood cell analyzer Lumiio was conducted as a national project under the Ministry of Trade, Industry and Energy's 'Mid-sized Enterprise Coexistence Innovation Project'. Last year, the national project was completed, and product upgrades and additional technologies for commercialization are being applied.
Previously, to perform morphological analysis of blood, processes such as blood smearing, fixation, drying, staining, washing, and drying were required, and manual observation through a microscope was necessary. Due to this, there were large deviations depending on the analyst's ability, and it took a long time.
Sinopex's blood cell analyzer Lumiio features the application of self-developed optical technology. With deep learning AI, morphological classification and analysis data of blood cells can be immediately verified on-site by doctors or examiners through a mobile phone or printer in about 10 minutes.
Sinopex has applied for a total of 9 patents, including this patent application, to protect intellectual property rights that may arise when Lumiio enters the domestic and overseas markets. Four patents have been registered, and five are under review.
A Sinopex representative said, "Initially, we aimed for mass production by the first half of this year, but the product launch has been postponed to the first half of 2026 due to ongoing additional technology development to enhance product competitiveness, such as glass substrate technology and AI accelerators."
They added, "The 20 or so blood cell test data provided by Lumiio not only offer basic information for diagnosing diseases such as inflammatory diseases, infections, allergic reactions, anemia, and platelet disorders but also enable new services that allow immediate verification of blood cell changes before and after dialysis on-site."
Meanwhile, Sinopex plans to create synergy with its artificial kidney business, which currently supplies blood filters for artificial kidneys to hospitals, in addition to blood cell testing with the Lumiio blood cell analyzer.

butter@fnnews.com Kang Kyung-rae Reporter